Ovarian cancer is the most lethal of all gynecological malignancies. This is in part because of the symptomology of the disease until it is at a late stage. Because of the five-year survival rate is only 45% while the actual cause of epithelial cancer of the ovary or fallopian tube is not known, studies have found about 15% are shown to be connected with the inherited genetic factors such as BRCA 1&2 mutations. The standard line of defense is surgery and treatment with platinum-based chemotherapy. Unfortunately, recurrence is high with the recurring disease resistant to further chemotherapy. Recently olaparib has shown some promise in treating BRCA 1&2 mutations that have led to ovarian cancer. It is thought this occurs along the DNA repair pathways that make the cancer cells sensitive to olaparib. The validity of the study's data was confirmed by repeated tests across different fields (Fleury et al. 2017).

Ovarian cancer begins in the female organs that produce eggs (ovaries), and often goes undetected until it has spread within the pelvis and stomach. The American cancer Society estimates that about 22,440 women will receive a new diagnosis of ovarian cancer in 2017. Usually women are advised to undergo surgery, chemotherapy, radiotherapy and other treatments that may incur lasting side effects and do not necessarily translate into surviving cancer. Though these mainstream cancer treatments are prioritized, there are other scientifically tested natural approaches to treat ovarian cancer.

Researchers at Kumamoto University in Japan say they have isolated a natural compound isolated from onions called onionin A (ONA) which has several properties that help fight ovarian cancer.

A commonly used class of heart medications known as beta-blockers is shown in a first study to improve ovarian cancer survival. The medications block tumor growth and spread by interfering with the stress pathway involved with cancer metastasis.